Validating Novel In Vitro Models & Building More Predictive Nonclinical Packages for Smarter ADC Preclinical Strategies
- Traditional nonclinical models often fail to predict clinical outcomes for complex ADCs, creating a need for more advanced and biologically relevant preclinical approaches.
- Novel in vitro systems can improve decision-making in drug discovery by providing better insights into key factors such as target uptake, payload characteristics, and tissue toxicity
- Integrating these systems into a broader translational strategy, along with improved species selection, biomarker use, and mechanistic data, can produce more predictive nonclinical packages and enable faster, more confident go/no-go decisions